These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 29955528)
1. Pimavanserin (Nuplazid™) for the treatment of Parkinson disease psychosis: A review of the literature. Touma KTB; Touma DC Ment Health Clin; 2017 Sep; 7(5):230-234. PubMed ID: 29955528 [TBL] [Abstract][Full Text] [Related]
2. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis. Meltzer HY; Mills R; Revell S; Williams H; Johnson A; Bahr D; Friedman JH Neuropsychopharmacology; 2010 Mar; 35(4):881-92. PubMed ID: 19907417 [TBL] [Abstract][Full Text] [Related]
3. Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis. Sahli ZT; Tarazi FI Expert Opin Drug Discov; 2018 Jan; 13(1):103-110. PubMed ID: 29047301 [TBL] [Abstract][Full Text] [Related]
4. Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist. Nasrallah HA; Fedora R; Morton R Schizophr Res; 2019 Jun; 208():217-220. PubMed ID: 30837203 [TBL] [Abstract][Full Text] [Related]
5. Pimavanserin for the treatment of Parkinson's disease psychosis. Chendo I; Ferreira JJ Expert Opin Pharmacother; 2016 Oct; 17(15):2115-24. PubMed ID: 27609312 [TBL] [Abstract][Full Text] [Related]
6. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Cummings J; Isaacson S; Mills R; Williams H; Chi-Burris K; Corbett A; Dhall R; Ballard C Lancet; 2014 Feb; 383(9916):533-40. PubMed ID: 24183563 [TBL] [Abstract][Full Text] [Related]
7. Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis. Bozymski KM; Lowe DK; Pasternak KM; Gatesman TL; Crouse EL Ann Pharmacother; 2017 Jun; 51(6):479-487. PubMed ID: 28375643 [TBL] [Abstract][Full Text] [Related]
8. Pimavanserin: First Global Approval. Markham A Drugs; 2016 Jul; 76(10):1053-7. PubMed ID: 27262680 [TBL] [Abstract][Full Text] [Related]
9. Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin. Majlath Z; Obal I; Vecsei L CNS Neurol Disord Drug Targets; 2017; 16(3):234-243. PubMed ID: 27719624 [TBL] [Abstract][Full Text] [Related]
13. Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis. Kianirad Y; Simuni T Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1161-1168. PubMed ID: 28817967 [TBL] [Abstract][Full Text] [Related]
14. Pimavanserin for the treatment of psychosis in Alzheimer's disease: A literature review. Srinivasan S; Tampi RR; Balaram K; Kapoor A World J Psychiatry; 2020 Jul; 10(7):162-174. PubMed ID: 32844093 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. Ballard C; Banister C; Khan Z; Cummings J; Demos G; Coate B; Youakim JM; Owen R; Stankovic S; Lancet Neurol; 2018 Mar; 17(3):213-222. PubMed ID: 29452684 [TBL] [Abstract][Full Text] [Related]
16. On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis. Hacksell U; Burstein ES; McFarland K; Mills RG; Williams H Neurochem Res; 2014 Oct; 39(10):2008-17. PubMed ID: 24682754 [TBL] [Abstract][Full Text] [Related]
17. Serotonin 2A Receptor Inverse Agonist as a Treatment for Parkinson's Disease Psychosis: A Systematic Review and Meta-analysis of Serotonin 2A Receptor Negative Modulators. Yasue I; Matsunaga S; Kishi T; Fujita K; Iwata N J Alzheimers Dis; 2016; 50(3):733-40. PubMed ID: 26757194 [TBL] [Abstract][Full Text] [Related]